ATRC atricure.com: Nilai perusahaan marang pendapatan

The medtech industry is shifting toward minimally invasive procedures, a trend confirmed by the robust clinical trial pipeline of AtriCure, Inc. (ATRC). AtriCure, Inc. (ATRC) generates revenue through the sale of high-margin arrhythmia management systems, strengthening its market position via the recognition of hybrid ablation and the success of AtriClip. The EV/Sales valuation multiple demonstrates the efficiency of sales capitalization, with the parameter value equal to 4518.82.
ATRC (AtriCure Medical): rincian analitis lan laporan miturut indikator

To minimize risks when selecting an asset, it is necessary to assess the real value of the business. The EV/Sales ratio compares the total value of the company (Enterprise Value) with its revenue, excluding the impact of debt load. By analyzing the history of EV/Sales changes, an investor can see the market consensus regarding profitability. For AtriCure, Inc. (ATRC), a decline in this metric may indicate rising costs due to the implementation of energy-saving technologies and eco-friendly device packaging.